{"id":469667,"date":"2021-04-01T08:33:26","date_gmt":"2021-04-01T12:33:26","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=469667"},"modified":"2021-04-01T08:33:26","modified_gmt":"2021-04-01T12:33:26","slug":"cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\/","title":{"rendered":"CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020<\/b><\/p>\n<p>\nFiscal Year 2020 Highlights:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nGenerated dramatic growth in total and pro forma revenue\n<\/li>\n<li>\nReleased positive clinical data on its patented drug delivery technology and received new certifications at its research facility\n<\/li>\n<li>\nAcquired and expanded consumer wellness subsidiary The Sera Labs, Inc.\n<\/li>\n<li>\nFiled and received approval on an IND application on its drug candidate for the treatment of erectile dysfunction, further validating the Company\u2019s core delivery platform CUREfilm\u00ae\n<\/li>\n<\/ul>\n<p>\n\u00a0\n<\/p>\n<p>OXNARD, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fcurepharmaceutical.com%2F&amp;esheet=52405303&amp;newsitemid=20210401005279&amp;lan=en-US&amp;anchor=CURE+Pharmaceutical+Holding+Corp.&amp;index=1&amp;md5=3564723c236c6a438f36c7c967b8ca4f\">CURE Pharmaceutical Holding Corp.<\/a> (OTC: CURR), a vertically integrated drug delivery and product development company, reported its financial and operating results for the year ended Dec. 31, 2020, and provided recent operational highlights.\n<\/p>\n<p>\nThe Company&#8217;s total revenue of $2.1 million rose 229% compared to fiscal year 2019. On a pro forma basis, which includes full year revenue generated from CURE\u2019s wholly owned subsidiary <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fseralabshealth.com%2F&amp;esheet=52405303&amp;newsitemid=20210401005279&amp;lan=en-US&amp;anchor=The+Sera+Labs%2C+Inc.&amp;index=2&amp;md5=b96f3f4d4e34061576d69786638237d6\">The Sera Labs, Inc.<\/a>, acquired October 2, 2020, revenue totaled $7.7 million. This compared to $3.0 million in 2019 pro forma revenue.\n<\/p>\n<p>\nGross profit increased to approximately $1.0 million from approximately $0.4 million in 2019.\n<\/p>\n<p><b>Operational Highlights for Fiscal Year 2020<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nReceived positive results from a pharmacokinetic (PK) study examining the bioavailability of CURE\u2019s proprietary CUREfilm\u00ae delivery system compared to soft gels;\n<\/li>\n<li>\nSecured NSF International, cGMP certification for its 25,000 square foot manufacturing facility;\n<\/li>\n<li>\nFiled and received FDA approval on its Investigational New Drug (IND) application for CUREfilm\u00ae Blue, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra\u00ae), designed for the treatment of erectile dysfunction (ED);\n<\/li>\n<li>\nAcquired The Sera Labs, a trusted leader in the health, wellness, and beauty sectors, further positioning CURE as an integrated healthcare company;\n<\/li>\n<li>\nSera Labs announced Nicole Kidman as the Global Brand Ambassador and Strategic Partner for all its topical product lines including its anti-aging skincare brand Seratopical;\n<\/li>\n<li>\nTogether, Sera Labs and CURE launched a new consumer product line, Nutri-Strips\u2122, leveraging CURE\u2019s patented and advanced novel oral film strip technology to deliver nutraceuticals to consumers nationally\n<\/li>\n<\/ul>\n<p>\n\u201cWe made great progress in 2020 and are now well positioned to become a fully integrated healthcare company, as propelled by the acquisition of Sera Labs,\u201d said Rob Davidson, CEO of CURE Pharmaceutical. \u201cWe have more than doubled our revenue in 2020, mostly through our wellness subsidiary Sera Labs. Meanwhile, we continue to forge ahead in our pharmaceutical research and development initiatives. These initiatives include our recently announced psychedelic and antiviral clinical programs which target high-growth, unmet need categories with leading compounds that leverage our proven drug delivery platform CUREfilm\u00ae.\u201d\n<\/p>\n<p><b>About CURE Pharmaceutical Holding Corp.<\/b><\/p>\n<p>\nCURE Pharmaceutical<sup>\u00ae<\/sup> is the pioneering developer of CUREform\u2122, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.\n<\/p>\n<p>\nAs a vertically integrated company, CURE\u2019s 25,000 square foot, FDA-registered, NSF<sup>\u00ae<\/sup> cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.\n<\/p>\n<p><b><i>Forward Looking Statement<\/i><\/b><\/p>\n<p><i>Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (\u201cSecurities Act\u201d), and Section 21E of the Securities Exchange Act of 1934, as amended (\u201cExchange Act\u201d), which are usually identified by the use of words such as \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cseeks,\u201d \u201cshould,\u201d \u201cwill,\u201d and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE\u2019s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.<\/i><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210401005279r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210401005279\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210401005279\/en\/<\/a><\/span><\/p>\n<p>\nLicensing Contact:<br \/>\n<br \/>Jonathan Berlent<br \/>\n<br \/>Chief Business Officer<br \/>\n<br \/>CURE Pharmaceutical<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:Jberlent@curepharma.com\">Jberlent@curepharma.com<br \/>\n<\/a><br \/>516.660.9148<\/p>\n<p>Investment Contact:<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@curepharma.com\">investors@curepharma.com<br \/>\n<\/a><\/p>\n<p>Gary Zwetchkenbaum<br \/>\n<br \/>Plum Tree Consulting LLC<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:gzplumtree@gmail.com\">gzplumtree@gmail.com<br \/>\n<\/a><br \/>516.455.7662<\/p>\n<p>Media Contact:<br \/>\n<br \/>Kathryn Brown<br \/>\n<br \/>CMW Media<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:cure@cmwmedia.com\">cure@cmwmedia.com<br \/>\n<\/a><br \/>858.264.6600\n<\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Alternative Medicine Health Fitness &amp; Nutrition Research Pharmaceutical Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020 Fiscal Year 2020 Highlights: Generated dramatic growth in total and pro forma revenue Released positive clinical data on its patented drug delivery technology and received new certifications at its research facility Acquired and expanded consumer wellness subsidiary The Sera Labs, Inc. Filed and received approval on an IND application on its drug candidate for the treatment of erectile dysfunction, further validating the Company\u2019s core delivery platform CUREfilm\u00ae \u00a0 OXNARD, Calif.&#8211;(BUSINESS WIRE)&#8211;CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, reported its financial and operating results for the year ended Dec. 31, 2020, and provided recent operational highlights. The &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-469667","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020 Fiscal Year 2020 Highlights: Generated dramatic growth in total and pro forma revenue Released positive clinical data on its patented drug delivery technology and received new certifications at its research facility Acquired and expanded consumer wellness subsidiary The Sera Labs, Inc. Filed and received approval on an IND application on its drug candidate for the treatment of erectile dysfunction, further validating the Company\u2019s core delivery platform CUREfilm\u00ae \u00a0 OXNARD, Calif.&#8211;(BUSINESS WIRE)&#8211;CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, reported its financial and operating results for the year ended Dec. 31, 2020, and provided recent operational highlights. The &hellip; Continue reading &quot;CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-01T12:33:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210401005279r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020\",\"datePublished\":\"2021-04-01T12:33:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\\\/\"},\"wordCount\":878,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210401005279r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\\\/\",\"name\":\"CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210401005279r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-04-01T12:33:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210401005279r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210401005279r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\/","og_locale":"en_US","og_type":"article","og_title":"CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020 - Market Newsdesk","og_description":"CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020 Fiscal Year 2020 Highlights: Generated dramatic growth in total and pro forma revenue Released positive clinical data on its patented drug delivery technology and received new certifications at its research facility Acquired and expanded consumer wellness subsidiary The Sera Labs, Inc. Filed and received approval on an IND application on its drug candidate for the treatment of erectile dysfunction, further validating the Company\u2019s core delivery platform CUREfilm\u00ae \u00a0 OXNARD, Calif.&#8211;(BUSINESS WIRE)&#8211;CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, reported its financial and operating results for the year ended Dec. 31, 2020, and provided recent operational highlights. The &hellip; Continue reading \"CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-01T12:33:26+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210401005279r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020","datePublished":"2021-04-01T12:33:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\/"},"wordCount":878,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210401005279r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\/","name":"CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210401005279r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-04-01T12:33:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210401005279r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210401005279r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cure-pharmaceutical-reports-increase-in-revenue-to-7-7-million-on-a-pro-forma-basis-in-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/469667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=469667"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/469667\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=469667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=469667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=469667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}